AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical company that discovers and delivers innovative medicines and ...

AbbVie is expected to post earnings of $2.90 per share for the current quarter, representing a year-over-year change of +3.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.4%.

Shares of AbbVie Inc. ABBV rose 1.42% to $201.47 Wednesday, on what proved to be an all-around positive trading session for ...

On April 10, 2025, AbbVie Inc. (NYSE:ABBV) stock closed at $174.20 per share with a market capitalization of $308.16 billion. ClearBridge Growth Strategy stated the following regarding AbbVie Inc ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

AbbVie to Buy Cancer Treatment Start-Up AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment. By Michael J. de la Merced and Andrew Pollack ...

AbbVie reported revenues of $15.1 billion in the last reported quarter, representing a year-over-year change of +5.6%. EPS of $2.16 for the same period compares with $2.79 a year ago.

Go Higher. AbbVie’s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It’s gone up by 100 percent since then. By Danny Hakim ...